I see this as a key expansion into women’s health, with HIMS aiming for over $1 billion in annual revenue next year from the “Hers” division. It’s a timely move to diversify after the earlier Wegovy partnership ended under regulatory pressure.
I’m optimistic but cautious—this new segment could be a real growth driver if adoption is strong. I’ll be watching upcoming earnings to see whether early excitement turns into sustained performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- Enid Bertha·2025-10-16TOPLike i said before, only a matter of time before reaching 75+1Report
- Merle Ted·2025-10-16TOPHow much more can it run1Report
- ElsieDewey·2025-10-16TOPWow, what a strategic move! 🚀 [Great]1Report